Nalaganje...
CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma
Primary effusion lymphoma (PEL) is an aggressive subtype of non-Hodgkin lymphoma characterized by short survival with current therapies, emphasizing the urgent need to develop new therapeutic approaches. Brentuximab vedotin (SGN-35) is an anti-CD30 monoclonal antibody (cAC10) conjugated by a proteas...
Shranjeno v:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Society of Hematology
2013
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3744990/ https://ncbi.nlm.nih.gov/pubmed/23838350 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-01-481713 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|